<DOC>
	<DOCNO>NCT02352051</DOCNO>
	<brief_summary>The aim study evaluate compare effect Atomoxetine ( ATX ) osmotic release oral system-methylphenidate ( OROS-MPH ) therapy executive function , activity , treatment response time adverse effect base discernible clinical effect child combine type attention deficit-hyperactivity disorder ( ADHD ) .</brief_summary>
	<brief_title>Effects Atx Oros-mph Executive Functions</brief_title>
	<detailed_description>The aim study evaluate compare effect Atomoxetine ( ATX ) osmotic release oral system-methylphenidate ( OROS-MPH ) therapy executive function , activity , treatment response time adverse effect base discernible clinical effect child combine type attention deficit-hyperactivity disorder ( ADHD ) . In study , functional capability patient clinically respond well therapy assess simultaneously clinical response may appear different time period treatment group compare patient respond therapy exclude patient insufficient clinical response .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Combined type ADHD diagnosis make child psychiatrist accord DSMIV criterion KSADS interview patient mother The Clinical Global Impression Scale ( CGIS ) apply determine ADHD severity patient CGIS scoreâ‰¥4 Psychological , neurological psychiatric disease ADHD , ADHD type combine type , Medication influence cognitive process history medication , WISCR score &lt; 80 &gt; 120</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>attention deficit-hyperactivity disorder ( ADHD ) .</keyword>
	<keyword>executive function</keyword>
</DOC>